Summit Therapeutics completesf $25 million subscription
Summit Therapeutics announces the subscription to raise $25 million has been completed. The subscription shares, comprising 78,125,000 new ordinary shares represented by 15,625,000 American Depositary Shares, were admitted to AIM and trading became effective Jan. 9, 2019. January 10, 2019